Summary
The authors report the results of a randomized, double-blind multicenter clinical trial on the use of gabexate mesilate vs aprotinin in the therapy of acute pancreatitis. The size of the study sample and the end points chosen for evaluation of the early systemic complications of the pancreatitis—carefully selected targets for reliable assessment of the efficacy of any protease inhibitor—lead to the conclusion that gabexate mesilate is more efficacious than aprotinin in reducing the early complications of necrotizing acute pancreatitis, if administered within 72 h of onset of symptoms. Its good tolerability means that it can be used safely even at the dose of 3 g/24 h.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wilson C, Imrie CW. Current concepts in the management of pancreatitis.Drugs 1991; 41: 358–366.
Trapnell JE, Rigby CC, Talbot CH. A controlled trial of Trasylol in the treatment of acute pancreatitis.Brit J Surg 1974; 61: 177–182.
Case AG. Death from acute pancreatitis. MRC multicenter trial of glucagon and aprotinin.Lancet 1977; 22: 632–635.
Imrie C.W, Benjamin IS, Ferguson JC. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis.Brit J Surg 1978; 65: 337–341.
Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon.Gut 1980; 21: 334–339.
Steinberg W, Schlesselman SE. Treatment of acute pancreatitis. Comparison of animal and human studies.Gastroenterology 1987; 93: 1420–1427.
Bassi C, Briani GF, Vesentini S. Continuous peritoneal dialysis in experimental acute pancreatitis in dogs. Effect of aprotinin in dialysate medium.Int J Pancreatol 1989; 5: 69–75.
Bassi C, Benetti L, Girelli R, Falconi M, Nifosi F, Coviello G, Cavallini G, Vesentini S, Dragonetti C, Pederzoli P. Early graft injuries after pancreatic transplantation in syngenic rats. Cytoprotective effects of gabexate mesilate.Int J Pancreatol 1991; 8 (4): 345–353.
Imrie CW, Mackenzie M. Effective aprotinin therapy in canine experimental bile-trypsin pancreatitis.Digestion 1981; 22: 32–38.
Wisner JR, Renner IG, Grendell JH, Nideran C, Ferrell LD. Gabexate mesilate (FOY), protects against ceruleine induced acute pancreatitis in the rat.Pancreas 1987; 2: 181–186.
Tani S, Otsuki M, Itoh H. The protective effect of the trypsin inhibitor urinastatin on cerulein induced acute pancreatitis in rats.Pancreas 1988; 3: 471–476.
Wisner IR, Ozawa S, Renner IG. The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat.Int J Pancreatol 1989; 4: 383–390.
Lankisch PG, Pohl U, Goke B, Otto J, Wereszczynska-Siemiatxowska V, Gröne HJ, Rahlf G. Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models.Gastroenterology 1989; 96: 193–199.
Tamura Y, Hirado M, Okamara K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r and C1 esterase.Biochim Biophys Acta 1977; 484: 417–422.
Freise J, Magerstedt P, Schmid K. Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinin.Enzyme 1983; 30: 209–212.
Balthazar EJ, Ranson JHC, Naidich DP, Megibow AJ, Caccavalle R, Cooper MM. Acute pancreatitis: prognostic value of CT.Radiology 1985; 156: 767–772.
Fritz H, Fink E, Trutscheit E. Kalikrein inhibitors.Fed Proc 1979; 38: 2753–2756.
Balladin G, Ohlsson K, Ohlsson AS. Studies on the influence of Trasylol on the partition of trypsin between the human plasma protease inhibitors in vitro.Hoppe-Seyler’s Z Physiol Chem 1978; 359: 691–694.
Freise J, Schmidt FW, Magerstedt P, Schmid K. Gabexate mesilate and camostate: new inhibitors of phospholipase A2 and their influence on the alpha-amylase activity in serum of patients with acute pancreatitis.Clin Biochem 1985; 18: 224–229.
Hollender LF, Lehnert P, Wanke M.Acute Pancreatitis. Urban & Schwarzenberg Publ., Munich, Vienna, Baltimore, 1983.
Benini L, Angelini G, Lavarini E, Brocco G, Cavallini G, Merigo F, Castagnini A, Piubello W, Rizzotti P, Scuro LA. Effect of a new enzyme inhibitor (gabexate mesilate—FOY) on hyperenzymemia induced by ERCP. A doubleblind study.Digestion 1985; 32: 155.
Scuro LA, Cavallini G, Bovo P, Riela A, Bassi C, Pederzoli P, Lazzarin GC, Corra S, Margiante G, Dagradi A, Dragonetti C, Marzoli GP, Pliteri S, Fontana G, Bressan GC, Lungarotti F, Mazzeo F. Gabexate mesilate (FOY) treatment of acute pancreatitis. An Italian multicenter pilot study.Clin Trials J 1990; 27: 39–49.
Goebell H. German Pancreatitis Study Group. Multicentre double blind study of gabexate mesilate (FOY) given intravenously in low dose in acute pancreatitis.Digestion 1988; 40: 83.
Büchler M, Malferteiner P, Uhl W, Wolf HR, Schwab G, Beger HG. Gabexate Mesilate in der Therapie der akuten Pancreatitis Multizenterstudie zur Vertaglichkeit einer hohen intravenosen Dosis (4 gr/Tag).Med Klin 1988; 83: 320–324.
Tanaka N, Tsuchiya R, Ishii K. Comparative clinical study of FOY and Trasylol in acute pancreatitis.Adv Exp Med Biol 1979; 1208: 367–378.
Büchler M, Malferteiner P, Uhl W, Schölmerich J, Stökmann F, Adler G, Rolle K, Ditschuneit H, Beger HG. Gabexate mesilate in human acute pancreatitis: results from the German Multicenter Trial with 4 gr/day.Digestion 1990; 46: 130.
Valderrama R, Perez-Mateo M, Navarro S, Vázquez N, Sanjosé J, Arian MJ, Estruch J. Multicenter double-blind trial of gabexate mesilate (FOY) in Unselected Patients with acute pancreatitis.Digestion 1992; 51: 65–70.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pederzoli, P., Cavallini, G., Falconi, M. et al. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). Int J Pancreatol 14, 117–124 (1993). https://doi.org/10.1007/BF02786117
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02786117